Indications and treatment outcomes of intravitreal bevacizumab and ranibizumab for retinal diseases in Benin City, Nigeria

Uhumwangho, Odarosa M

doi:10.4103/0189-9171.207371

Cited by 4 publications

(9 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though our patients had been counselled on the need to have the recommended monthly dose of 3 injections, only about 27.5% (50) complied to regimen and 51.7% (94) had only one injection due to financial constraints as they pay out of pocket. The average number of injections in this cohort (1.8 ± 0.9) is akin to a similar study reported in a tertiary hospital in Benin, 16 but at variance with the higher mean number of injections reported in major landmark clinical trials that have shaped the preferred practice pattern for intravitreal anti-VEGF injections. 2,8–10,12 A strong health system with an effective financial payment and insurance coverage could have been the reason for this disparity.…”

Section: Discussionsupporting

confidence: 78%

“…The average number of letters gained was highest at one-month post-injection but was not sustained as it declined to 13 and finally to 8.5 letters (1.7 lines) at 12-month but this improvement was still a statistically significant outcome. Uhumwangho 16 similarly reported visual improvement in about 50% of studied patients. Pham et al, 2 in their systematic review and meta-analysis reported varying levels of visual outcomes depending on the specific disease.…”

Section: Discussionmentioning

confidence: 74%

“…The mean age of patients involved in this study is similar to that in other centres in Nigeria. [14][15][16][17] But, the wide age range was due to the inclusion of babies who received anti-VEGF for retinopathy of prematurity. Almost all our patients,180 (98.9%) had the less expensive bevacizumab injection, which is akin to other studies done both locally.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Visual outcome of Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan

Oluleye

Babalola

Majekodunmi

et al. 2020

Preprint

View full text Add to dashboard Cite

Aim: To evaluate the four-year outcome of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in an eye unit in sub-Saharan Africa. Methodology: This retrospective study included 182 eyes of 172 patients managed in the vitreoretinal unit between 2016 and 2019 who were treated with intravitreal anti-VEGF Bevacizumab (1.25 mg/0.05 ml) with at least one year of follow up. The outcome measures were: change in best-corrected visual acuity (BCVA) over one year of follow-up, the number of injections taken and complications. Results: The mean age was 61.1 (SD=16.3) years (M: F of 1:1.1) and about 62.1% were > 60 years. A total of 330 injections were given during the period audited. The mean number of injections was 1.8 (SD=0.93). Ninety-four (51.7%) eyes had only one injection while 33 (18.1%), 50 (27.5%) and 5 (2.7%) had 2, 3 and 4 injections, respectively. About 78.5% had moderate-severe visual impairment (MSVI) at baseline and 44.5%, 16.4%,12.6% and 7.1% at 1, 3, 6- and 12-months post injections, respectively. The mean BCVA improved for all eyes from 1.67 (SD=0.91) logMAR at baseline to 1.50 (SD=1.27) logMAR at one year. The logMAR letters gained was 23 at 1 month and 8.25 at 1 year with a statistically significant association between increasing number of injections and improved visual outcome (p= 0.015). One patient each developed endophthalmitis (0.6%) and inferior retinal detachment (0.6%) post-injection. Conclusion: Visual acuity gain was recorded in patients who had at least two intravitreal Anti-VEGF injections in 1 year. Keywords: Intravitreal injections, bevacizumab (Avastin), ranibizumab (Lucentis), anti-VEGF, visual outcome

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Visual outcome of Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan

Oluleye

Babalola

Majekodunmi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…This is similar to a study Fiebai et al, 7 but at variance with the report from Port-Harcourt and from other centres in Nigeria where diabetic retinopathy/ diabetic maculopathy was reported as the most common indication. 8,9,10,11 This disparity may be from the peculiarity of our centre (University College Hospital, Ibadan) being a larger centre that receives more referral from many states in the country. Surprisingly, the proportion of patients treated for diabetic retinopathy had doubled over the 5 years when compared to the last audit.…”

Section: Discussionmentioning

confidence: 99%

Changing indications for intravitreal Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan, sub-Saharan Africa

Adewole

Oluleye

Babalola

et al. 2020

Preprint

View full text Add to dashboard Cite

Aim: To compare the current indications for intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, to make recommendations for planning of services. Methodology: The medical records of 172 patients who had intravitreal anti-VEGF injections from January 2016 to December 2019 were retrieved. Socio-demographic and clinical data were extracted, analysed, and compared with data from the previously published audit report covering 2010 to 2012. Results: Three hundred and thirty injections were given to 182 eyes in this cohort of patients. The mean age was 61.1 (SD=16.3) years (range <1-90 years), with a male to female ratio of 1.1:1. Retinal vein occlusion, 64 (35%) remained the most common indication for anti-VEGF injections in the eyes treated. This was followed by choroidal neovascular membrane/ Wet age-related macular degeneration which accounted for 42 (23%) as reported previously. However, cases of proliferative diabetic retinopathy/ diabetic maculopathy needing anti-VEGF were noticed to have almost doubled from about 8% (10) in the previous study to 15% (27) in the present study. In addition, idiopathic polypoidal choroidal vasculopathy, 18 (10%) ranked above proliferative sickle cell retinopathy in the present study. Retinopathy of prematurity, neovascular glaucoma, retinal artery macro-aneurysm and myopic choroidal neovascular membrane were the new emerging indications. Conclusion: There is an expanding indication for anti-VEGF in the management of retinal vascular diseases in our health facility and adequate measures should be put in place for early diagnosis and management. Patients should be counselled on the availability of this treatment option. Keywords: retinal diseases, intravitreal injections, anti-VEGF therapy, indications

show abstract

“…This is similar to report of the review by Fiebai et al,7 in Port-Harcourt but at variance with the findings from other centres in Nigeria where diabetic retinopathy/ diabetic maculopathy was reported as the most common indication. [7][8][9][10][11] This disparity may be from the peculiarity of the centre (university college hospital, Ibadan) being a larger centre that receives more referral from many states in the country. Surprisingly, the proportion of patients treated for diabetic retinopathy had doubled over the 5 years when compared to the last audit.…”

Section: Discussionmentioning

confidence: 99%

Changing indications for intravitreal anti-vascular endothelial growth factor injections at the university college hospital, Ibadan, Sub-Saharan Africa

et al. 2020

View full text Add to dashboard Cite

Background: Compare the current indications for intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, to make recommendations for planning of services. To review the current indications for intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, in order to make recommendations for planning of services.Methods: The medical records of 172 patients who had intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections from January 2016 to December 2019 were retrieved. Socio-demographic and clinical data were extracted, analysed, and compared with data from the previously published audit report covering 2010 to 2012.Results: Three hundred and thirty injections were given to 182 eyes in this cohort of patients. The mean age was 61.1±16.3 years (range <1-90 years), with a male to female ratio of 1.1:1. Retinal vein occlusion, 64 (35%) remained the most common indication for anti-VEGF injections in the eyes treated. This was followed by choroidal neovascular membrane/wet age-related macular degeneration which accounted for 42 (23%) as reported previously. However, cases of proliferative diabetic retinopathy/ diabetic maculopathy needing anti-VEGF were noticed to have almost doubled from about 8 (10%) in the previous study to 15 (27%) in the present study. In addition, idiopathic polypoidal choroidal vasculopathy, 18 (10%) ranked above proliferative sickle cell retinopathy in the present study. Retinopathy of prematurity (ROP), neovascular glaucoma, retinal artery macro-aneurysm and myopic choroidal neovascular membrane were the new emerging indications.Conclusion: There is an expanding indication for anti-VEGF in the management of retinal vascular diseases in the health facility and adequate measures should be put in place for early diagnosis and management. Patients should be counselled on the availability of this treatment option.

show abstract

Indications and treatment outcomes of intravitreal bevacizumab and ranibizumab for retinal diseases in Benin City, Nigeria

Cited by 4 publications

References 1 publication

Visual outcome of Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan

Visual outcome of Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan

Changing indications for intravitreal Anti-Vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan, sub-Saharan Africa

Changing indications for intravitreal anti-vascular endothelial growth factor injections at the university college hospital, Ibadan, Sub-Saharan Africa

Contact Info

Product

Resources

About